Advertisement
Canada markets close in 5 hours 25 minutes
  • S&P/TSX

    22,304.61
    -42.15 (-0.19%)
     
  • S&P 500

    5,313.31
    +6.30 (+0.12%)
     
  • DOW

    39,385.75
    -285.29 (-0.72%)
     
  • CAD/USD

    0.7304
    -0.0002 (-0.02%)
     
  • CRUDE OIL

    77.96
    +0.39 (+0.50%)
     
  • Bitcoin CAD

    93,039.12
    -2,426.00 (-2.54%)
     
  • CMC Crypto 200

    1,475.62
    -27.04 (-1.80%)
     
  • GOLD FUTURES

    2,353.90
    -39.00 (-1.63%)
     
  • RUSSELL 2000

    2,072.62
    -9.09 (-0.44%)
     
  • 10-Yr Bond

    4.4930
    +0.0590 (+1.33%)
     
  • NASDAQ

    16,917.39
    +115.84 (+0.69%)
     
  • VOLATILITY

    12.17
    -0.12 (-0.98%)
     
  • FTSE

    8,351.42
    -18.91 (-0.23%)
     
  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     
  • CAD/EUR

    0.6740
    -0.0005 (-0.07%)
     

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

Certara
Certara

PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.

Certara also announced that Company management will participate at the upcoming BofA Securities Healthcare Conference.

ADVERTISEMENT

Company management will present at 3:40PM PT on Tuesday, May 14th.

Live and archived webcasts of both the financial results conference call and the BofA presentation will be available on the “Investors” section of the Certara website at https://ir.certara.com/.

About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,300 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries. Visit us at www.certara.com.

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Pan Communications
Certara@pancomm.com